单片联合制剂在高血压治疗中优势.pptxVIP

Treatment Strategies in Hypertension and the Role of Single Pill Combination;Issues to Adress;Choice of antihypertensive drugs;;;;Which strategy to adopt if initial Monotherapy at standard dose Fails？ ;Percentage of Patients Reaching a Target SBP140 mmHg with Different Classes of Antihypertensive Agents;Ratio of observed to expected incremental blood pressure-lowering effects* of adding a drug or doubling the dose according to the class of drug ;Greater BP Reductions by Combination Treatment;;Combination Treatment;Possible combinations of antihypertensive drug classes;Preferred combinations;17089 M;Major drug combinations used in trials of antihypertensive treatment in a step-up approach or as a randomized combination;Hazard Ratios for Primary and Secondary Endpoints (olmesartan + CCB or D; n = 5658);Total and Selected Endpoints Cumulative Event-Rate Curves;;RAS blocker+ CCB vs. RAS blocker+ Diuretics;;;Does treatment simplification really improve adherence to treatment? ;Compliance Usually Decreases as Pill Burden Increases;;Improved Compliance with Single-pill Combination Therapy Compared with Free-combination Therapy;Adherence to treatment with fixed vs free combinations;; Single Pill Improves adherence with absence/presence of CVD diagnosis ;Increase in Adherence to Treatment by FDCs Regardless Concomitant Medications;Effect of Fixed-dose vs Free-drug Combinations on the Risk of Medication Non-compliance;Does improvement of adherence enhance the beneficial effects of treatment?;Factors Involved in Poor Control of Risk Factors;0;Systolic and Diastolic Blood Pressure Normalisation Ratios Associated with Use of an SPC as Compared with Its Free-drug Combination;;;Better Compliance with Antihypertensive Drugs Leads to a Lower Risk of Hospitalization;Persistence or Adherence with Antihypertensive Drug Therapy and CV Risk (n = 242.594 / n = 12.016 hospital admissions for CAD / strokes);Association between Adherence to Placebo and Mortality;Association be